Contributor Profile

Sekyoo Jeong

Job TitleDirector / CTO

Company NameIncospharm Corporation


Dr. Jeong’s main research area encompasses new cosmetic ingredient development, bioactivity evaluation system development, and investigating skin barrier function.

During the last 20 years, he has been dedicated to the basic and clinical research on skin barrier functions, focusing on development of new cosmetic ingredients. He successfully introduced new cosmetic ingredients into the market, including pseudoceramides, epidermal anti-microbial peptides (AMPs) stimulating ingredients, protease-activated receptor-2 (PAR-2) inhibitor, and skin cannabinoid receptor agonist.

Based on long-term experiences in industry and academia, he is currently focusing on developing topical autophagy activators for cosmetic application.

Based on the important roles of autophagy for skin homeostasis, autophagy is getting more interests as an attractive target for cosmetic applications, including anti-aging, skin whitening, sebogenesis regulator, and anti-inflammatory ingredients.

He and his team in Incospharm Corp. already successfully introduced series of autophagy-based cosmeceutical ingredients, including Award-winning Aquatide, Adiposol, and MelaTrepein.

Conference Sessions

  • Extracellular roles of autophagy - Restoration of healthy hydrolipidic film

    Wednesday15:00 - 15:3026 Jun 2019
    Technical Seminars Theatre

    Autophagy, an “intracellular housekeeping” machinery for healthy and beautiful skin, has emerged as an important and attractive target for cosmetic applications...

    • Language: Korean

We use cookies to operate this website and to improve its usability. Full details of what cookies are, why we use them and how you can manage them can be found by reading our Privacy & Cookies page. Please note that by using this site you are consenting to the use of cookies.